首页> 外文期刊>American Journal of Case Reports >Chordoma: A Case Report and Review of Literature
【24h】

Chordoma: A Case Report and Review of Literature

机译:脊索瘤:文学的案例报告和审查

获取原文
           

摘要

Patient: Female, 68-year-old Final Diagnosis: Chordoma Symptoms: Hoarseness ? neck pain ? weakness Medication: — Clinical Procedure: — Specialty: Oncology Objective: Unusual or unexpected effect of treatment Background: Chordoma is rare, but aggressive bone tumor, primarily affecting the axial skeleton. Systemic chemotherapies are not effective against the tumor, and treatment primarily consists of surgical resection and radiation. Despite these treatment modalities, recurrence is common. Our case highlights the role of afatinib as an effective treatment option in such cases. Case Report: We present case of 68-year-old female with chordoma, who underwent multiple surgical resections, radiotherapy session, and had course complication by disease progression on imatinib and local recurrence. She was eventually placed on afatinib with good effect. Conclusions: This article discusses the effectiveness of afatanib as a treatment modality, along with diagnosis, histopathological features, associated genetic aberrations, currently available and upcoming treatment options. Special emphasis is placed on molecular targeted therapy, emerging immunotherapies and use of vaccination in this field.
机译:病人:女性,68岁的最终诊断:脊索瘤症状:嘶哑?颈部疼痛 ?弱点药物: - 临床手术: - 专业:肿瘤学目标:治疗背景不寻常或意外效果:脊索瘤是罕见的,但积极的骨肿瘤,主要影响轴向骨架。全身化疗对肿瘤无效,治疗主要包括手术切除和辐射。尽管这些治疗方式,复发是常见的。我们的案例突出了AFATINIB在这种情况下作为有效治疗选项的作用。案例报告:我们为68岁女性患有脊索瘤的案例,他们接受了多次外科切除,放射治疗会议,并通过疾病进展对伊马替尼和局部复发进行了疾病的并发症。她最终被安置在阿杜蒂米上,效果良好。结论:本文讨论了Afatanib作为治疗方式的有效性,以及诊断,组织病理学特征,相关的遗传畸变,目前可用和即将到来的治疗方案。特别强调分子靶向治疗,新出现的免疫疗法和在该领域的使用疫苗接种。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号